181 related articles for article (PubMed ID: 33496749)
1. Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop.
Fahy L; Calvo J; Chabi S; Renou L; Le Maout C; Poglio S; Leblanc T; Petit A; Baruchel A; Ballerini P; Naguibneva I; Haddad R; Arcangeli ML; Mazurier F; Pflumio F; Uzan B
Blood Adv; 2021 Jan; 5(2):513-526. PubMed ID: 33496749
[TBL] [Abstract][Full Text] [Related]
2. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
Frolova O; Samudio I; Benito JM; Jacamo R; Kornblau SM; Markovic A; Schober W; Lu H; Qiu YH; Buglio D; McQueen T; Pierce S; Shpall E; Konoplev S; Thomas D; Kantarjian H; Lock R; Andreeff M; Konopleva M
Cancer Biol Ther; 2012 Aug; 13(10):858-70. PubMed ID: 22785211
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
4. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.
Hudson CC; Liu M; Chiang GG; Otterness DM; Loomis DC; Kaper F; Giaccia AJ; Abraham RT
Mol Cell Biol; 2002 Oct; 22(20):7004-14. PubMed ID: 12242281
[TBL] [Abstract][Full Text] [Related]
5. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the proliferation of hypoxia-Induced retinal pigment epithelial cell by rapamycin through the /mTOR/HIF-1α/VEGF/ signaling.
Liu NN; Zhao N; Cai N
IUBMB Life; 2015 Jun; 67(6):446-52. PubMed ID: 25988388
[TBL] [Abstract][Full Text] [Related]
8. Silent Information Regulator 1 Negatively Regulates Atherosclerotic Angiogenesis via Mammalian Target of Rapamycin Complex 1 Signaling Pathway.
Chen R; Huang Z; Wang J; Chen X; Fu Y; Wang W
Am J Med Sci; 2018 Aug; 356(2):168-176. PubMed ID: 30219159
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Siah2 Ubiquitin Ligase by Vitamin K3 Attenuates Chronic Myeloid Leukemia Chemo-Resistance in Hypoxic Microenvironment.
Huang J; Lu Z; Xiao Y; He B; Pan C; Zhou X; Xu N; Liu X
Med Sci Monit; 2018 Feb; 24():727-735. PubMed ID: 29400343
[TBL] [Abstract][Full Text] [Related]
10. Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions.
Ushijima H; Suzuki Y; Oike T; Komachi M; Yoshimoto Y; Ando K; Okonogi N; Sato H; Noda SE; Saito J; Nakano T
J Radiat Res; 2015 Jul; 56(4):663-8. PubMed ID: 25887043
[TBL] [Abstract][Full Text] [Related]
11. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
[TBL] [Abstract][Full Text] [Related]
12. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
[TBL] [Abstract][Full Text] [Related]
14. Clk1-regulated aerobic glycolysis is involved in glioma chemoresistance.
Zhang L; Yang H; Zhang W; Liang Z; Huang Q; Xu G; Zhen X; Zheng LT
J Neurochem; 2017 Aug; 142(4):574-588. PubMed ID: 28581641
[TBL] [Abstract][Full Text] [Related]
15. Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy.
Spinello I; Quaranta MT; Paolillo R; Pelosi E; Cerio AM; Saulle E; Lo Coco F; Testa U; Labbaye C
Haematologica; 2015 Sep; 100(9):1160-71. PubMed ID: 26045293
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
[TBL] [Abstract][Full Text] [Related]
17. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression.
Sowa T; Menju T; Chen-Yoshikawa TF; Takahashi K; Nishikawa S; Nakanishi T; Shikuma K; Motoyama H; Hijiya K; Aoyama A; Sato T; Sonobe M; Harada H; Date H
Cancer Med; 2017 Jan; 6(1):288-297. PubMed ID: 28028936
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
20. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
